BioAge Labs, Inc. (BIOA) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-04-24

Key Insights

CFO Dov Goldstein acquired 3,542 shares of common stock at $4.38 per share on April 23, 2026, bringing his total beneficial ownership to 36,575 shares, indicating confidence in the company's valuation at this price point.
The transaction includes a stock option grant of 3,542 shares with the same exercise price ($4.38), featuring a standard 4-year vesting schedule with monthly increments (1/48th per month), beginning February 1, 2025, which is typical executive compensation structure.
This insider purchase by a C-suite executive (CFO) during the April 2026 timeframe suggests management's positive outlook on the company, though the transaction appears to be primarily option/equity compensation rather than a voluntary market purchase.

Want the newest filings?

This analysis covers the filing from 2026-04-24. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-04-03

The reporting person, Paul D. Rubin, exercised stock options and immediately sold the resulting shares, indicating potential liquidation of his stake in the company.
The transactions were executed pursuant to a pre-established Rule 10b5-1 trading plan, suggesting planned and systematic insider selling.
The exercise prices of $4.11 and $6.57 are significantly lower than the reported sale price of $17.81, potentially signaling favorable market conditions or growth prospects for the company.

Filed: 2026-03-03

The reporting person, Paul D. Rubin, the Chief Medical Officer of BioAge Labs, Inc., exercised 7,433 stock options at an average exercise price of $5.34 and sold all of the resulting shares at $20.3 per share.
The stock option exercises and sales appear to be part of a Rule 10b5-1 trading plan, indicating a planned and structured approach to managing the reporting person's equity holdings.
The reporting person continues to hold 3,383 remaining stock options, suggesting an ongoing commitment to the company and alignment with shareholder interests.

Filed: 2026-03-03

Dov A. Goldstein, the Chief Financial Officer of BioAge Labs, Inc. (BIOA), exercised 3,542 stock options at an exercise price of $4.38 per share on March 1, 2026.
Goldstein's total beneficial ownership of BIOA common stock increased to 33,033 shares following the transaction, indicating his continued commitment to the company.
The option exercise was part of Goldstein's compensation package and likely aligns his interests with those of BIOA shareholders.

Filed: 2026-02-19

Paul D. Rubin, the Chief Medical Officer of BioAge Labs, Inc. (BIOA), has acquired 110,000 stock options with an exercise price of $19.63 and a vesting period of 4 years, indicating his long-term commitment to the company.
The options grant suggests that the company is incentivizing its key executives to drive the company's growth and development, aligning their interests with those of shareholders.
Insider transactions like this can provide insights into management's confidence in the company's future prospects and their alignment with shareholders' interests.

Filed: 2026-02-19

Eric Morgen, the Chief Operating Officer of BioAge Labs, Inc., acquired 110,000 stock options and 12,500 stock options granted to his spouse, indicating insider confidence in the company's prospects.
The stock options are subject to a 4-year vesting schedule, with the first tranche vesting on February 1, 2026, aligning Morgen's interests with long-term shareholder value creation.
The exercise price of the options is $19.63, which suggests the company's management believes the stock is undervalued and presents an attractive investment opportunity for insiders.

Filed: 2026-02-19

Dov A. Goldstein, the Chief Financial Officer of BioAge Labs, Inc. (BIOA), has acquired 110,000 stock options with an exercise price of $19.63 and a vesting period of 4 years.
The acquisition of these options suggests that Goldstein is confident in the company's future growth and is willing to take a long-term stake in the organization.
The significant number of options granted to Goldstein, a key executive, may indicate that BioAge Labs is focusing on incentivizing and retaining its leadership team to drive the company's success.

Filed: 2026-02-19

Kristen Fortney, the CEO of BioAge Labs, acquired 330,000 stock options on February 17, 2026, suggesting strong insider confidence in the company's future prospects.
The options vest monthly over a 4-year period, aligning Fortney's incentives with long-term shareholder value creation.
This transaction represents a significant increase in Fortney's beneficial ownership, potentially signaling her commitment to the company's success.

Filed: 2026-02-19

The reporting person, Shane Barton, who is the Principal Accounting Officer, acquired 45,000 stock options with an exercise price of $19.63 and a 10-year expiration date.
The options vest monthly over 4 years, indicating the company is providing long-term equity incentives to its key accounting officer.
The timing of the option grant suggests the company is making strategic investments in its finance and accounting team to support its ongoing operations and future growth.

Filed: 2026-01-21

Dov A. Goldstein, the Chief Financial Officer of BioAge Labs, Inc. (BIOA), exercised 3,542 stock options at an exercise price of $4.38 on January 16, 2026.
Goldstein's exercise of these options increased his direct beneficial ownership of BIOA common stock to 25,950 shares.
The options exercised had an expiration date of February 17, 2035, and vested monthly over a four-year period starting from February 1, 2025.

Filed: 2026-01-15

Kristen Fortney, the CEO of BioAge Labs, Inc. (BIOA), has sold 233,107 shares of the company's common stock on January 13, 2026, at a weighted average price of $18.1163 per share.
The sale was executed pursuant to a pre-arranged Rule 10b5-1 trading plan, indicating a planned transaction rather than an opportunistic sale.
Following the reported transaction, Fortney still holds 976,949 shares of the company's common stock, suggesting she maintains a significant ownership position.

Filed: 2026-01-15

The reporting person, Dov A. Goldstein, who is the Chief Financial Officer of BioAge Labs, Inc., exercised 27,000 stock options and then sold 27,000 shares of the company's common stock on January 13, 2026.
The reported sales were executed pursuant to a Rule 10b5-1 trading plan, suggesting planned and structured insider selling rather than opportunistic trades.
The average sale prices ranged from $18.43 to $21.08 per share, indicating the CFO was able to sell the shares at favorable market prices.

Filed: 2026-01-06

The Chief Medical Officer, Paul D. Rubin, exercised stock options and sold a significant amount of shares, potentially signaling a change in his outlook or a need for liquidity.
The options exercised and shares sold were pursuant to a pre-established 10b5-1 trading plan, indicating the transactions were planned in advance.
The timing of the transactions, occurring at the start of the year, may provide insight into management's views on the company's near-term prospects.

Other reports for BioAge Labs, Inc.

Current Report Quarterly Report Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.